MIR18A (MicroRNA 18a)

Our study reveals that low FENDRR expression is a poor prognostic indicator in BCa. FENDRR inhibits miR-18a-5p to upregulate ESR1 and hinder cancer progression, suggesting potential therapeutic targets.

The miR-18a-5p/CYP1A1/PPAR axis is a novel pathway that could be targeted for AFL treatment.

DCA indicated that the model had clinical application value. The Nomogram model for recurrence after laparoscopic radical cystectomy procedure for BC has good prediction ability.

Overall, current evidence supports miRNAs as promising diagnostic, prognostic, and predictive biomarkers in cutaneous oncology. Standardized methodologies and large-scale validation remain essential for their integration into routine clinical practice.

These structured regions coincide with conserved motifs associated with NF-κB p50 and predicted miRNA binding sites, indicating that PACER function may depend on conformational switching that modulates protein and miRNA accessibility. Together, these findings establish PACER as a regulator of LUAD proliferation and invasion via COX-2 signaling and highlight its potential as a biomarker and therapeutic target in inflammatory cancers.

The miR-18a-5p served as a predictive factor and held diagnostic significance for PRAEs following general anesthesia in children. Additionally, miR-18a-5p may offer potential therapeutic implications for PRAEs.

The Editor apologizes to the readership for any inconvenience caused. [Oncology Reports 33: 2853‑2862, 2015; DOI: 10.3892/or.2015.3929].

Moreover, epigenetic silencing of miR-203 enhances BCR::ABL1 expression, further contributing to TKI resistance. These small regulatory RNAs consequently act for promising candidates both as therapeutic targets and as prognostic biomarkers, with the potential to fill treatment gaps that persist even in the TKI era.

Overall, this study highlights the utility of 3D cultures in investigating the biology of breast cancer, emphasizing the critical interplay between lncRNAs, miRNAs, and mRNAs. Our findings provide insights into the discovery of novel potential biomarkers, underscoring the importance of integrating both in vitro 3D culture and in vivo expression data for a more accurate identification of miRNAs with possible applications in cancer therapies.

Our investigation indicated that this gene might affect varied stages of breast cancer cell lines' cellular properties, such as cell duplication, morphology, and growth. It might also contribute to tumor formation in more aggressive cell lines like MDA-MB-231 in vivo.

These interconnected circuits offer novel insights into treatment resistance and stem cell persistence, identifying promising therapeutic targets. Future validation of these interactions may guide the development of non-coding RNA-targeted therapies for resistant CML.